<DOC>
	<DOCNO>NCT01297036</DOCNO>
	<brief_summary>To compare relative bioavailability pharmacokinetic characteristic newly develop donepezil formulation conventional formulation healthy subject single dose , randomize , open-label , 2-sequence -2period crossover study .</brief_summary>
	<brief_title>Pharmacokinetic Comparisons Two Donepezil Formulations</brief_title>
	<detailed_description>This single dose , open label , balance , randomize , two-treatment , two-period , two-sequence , crossover study conduct compare relative bioavailability pharmacokinetic characteristic newly develop formulation conventional formulation healthy subject . For , single-center , randomize , single-dose , open-label , 2-way crossover study 21-day washout period conduct 22 healthy volunteer . Plasma sample analysis donepezil collect 240 h drug administration . Participants receive either reference test drug formulation 10 mg donepezil first period alternative formulation second period . Plasma concentration donepezil determine validated high-performance liquid chromatography couple tandem mass spectrometry detection . Pharmacokinetic parameter , include Cmax AUC , determine noncompartmental analysis . Analysis variance ( ANOVA ) carry use log-transformed Cmax AUC , mean ratio 90 % confidence interval ( CI ) calculate . According regulatory requirement set forth Korea US Food Drug Administration , product meet criterion bioequivalence 90 % CIs mean ratio Cmax AUC within range 0.80 1.25 .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Males age 20 45 year Body weight &gt; 45 kg +/ 20 % ideal body weight Signed date informed consent form meet criteria current FDA KFDA regulation subject acute condition . presence history affect ADME Clinically significant history current evidence hepatic , renal , gastrointestinal , hematologic abnormality Hepatitis B , hepatitis C , HIV infection reveal laboratory finding Any acute chronic disease A history hypersensitivity donepezil A history alcohol drug abuse Participation another clinical trial within 3 month smoke &gt; 10 cigarette daily consumption 5 glass daily beverage contain xanthine derivative use medication potential affect study result within 10 day start study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Donepezil</keyword>
</DOC>